Prelude Therapeutics Incorporated (PRLD)
NASDAQ: PRLD · Real-Time Price · USD
1.300
+0.412 (46.40%)
At close: Dec 20, 2024, 4:00 PM
1.280
-0.020 (-1.54%)
After-hours: Dec 20, 2024, 7:59 PM EST

Prelude Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 2018
Period Ending
Sep '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 2018
Net Income
-131.52-121.83-115.44-111.69-56.93-27.57
Upgrade
Depreciation & Amortization
1.611.171.320.920.540.38
Upgrade
Loss (Gain) From Sale of Assets
----0.010.01
Upgrade
Loss (Gain) From Sale of Investments
-4.76-3.472.591.36--
Upgrade
Stock-Based Compensation
23.4825.6225.1420.935.580.85
Upgrade
Other Operating Activities
1.811.941.721.33--
Upgrade
Change in Accounts Payable
1.03-2.27-0.353.91.160.55
Upgrade
Change in Other Net Operating Assets
2.62-8.211.28-0.283.460.12
Upgrade
Operating Cash Flow
-105.72-107.06-83.73-83.53-46.18-25.67
Upgrade
Capital Expenditures
-1.84-3.51-3.02-2.32-0.62-0.78
Upgrade
Investment in Securities
77.65-31.1384.71-261.48--
Upgrade
Investing Cash Flow
75.81-34.6581.69-263.8-0.62-0.78
Upgrade
Long-Term Debt Repaid
-----0.26-0.12
Upgrade
Net Debt Issued (Repaid)
-0.24----0.26-0.12
Upgrade
Issuance of Common Stock
25.55136.410.82165.2166.730.01
Upgrade
Repurchase of Common Stock
-0.05-0.02----
Upgrade
Other Financing Activities
-0.11---0.3-0.01-
Upgrade
Financing Cash Flow
25.15136.40.82164.9246.2329.73
Upgrade
Net Cash Flow
-4.76-5.31-1.22-182.44199.433.28
Upgrade
Free Cash Flow
-107.56-110.58-86.75-85.85-46.8-26.45
Upgrade
Free Cash Flow Per Share
-1.45-1.83-1.83-1.86-3.75-15.85
Upgrade
Levered Free Cash Flow
-61.55-58.93-50.12-46.86-25.58-16.34
Upgrade
Unlevered Free Cash Flow
-61.55-58.93-50.12-46.86-25.58-16.34
Upgrade
Change in Net Working Capital
-4.73-0.48-3.64-4.7-5.64-0.79
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.